NCT00503035 2023-02-13
Molecular Targeting of 15-Lipoxygenase-1 (15-LOX-1) for Apoptosis Induction in Human Colorectal Cancers
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
14 trialsNCT03403634 2022-03-02
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
Roswell Park Cancer Institute
Phase 2 Completed
NCT00033371 2020-09-29
Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis
National Cancer Institute (NCI)
Phase 2 Completed
NCT02280694 2020-02-12
LDMchemoCRC
HaEmek Medical Center, Israel
Phase 2 Completed
NCT00582660 2017-06-15
UAB0040
University of Alabama at Birmingham
Phase 2 Completed
NCT00043043 2013-06-19
Celecoxib in Preventing Cancer in Patients With Rectal Polyps or Colorectal Neoplasia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00258232 2013-04-08
Celecoxib, Capecitabine, and Irinotecan in Treating Patients With Recurrent or Metastatic Colorectal Cancer
Barbara Ann Karmanos Cancer Institute
Phase 2 Completed
NCT00336960 2013-03-05
Celecoxib, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00084721 2013-01-31
Irinotecan and Celecoxib in Treating Patients With Unresectable or Metastatic Colorectal Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT00466505 2012-12-19
Cetuximab & Celecoxib for Metastatic Colorectal Cancer or Colorectal Cancer That Cannot Be Removed by Surgery
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00064181 2012-09-24
Combination Chemotherapy With or Without Celecoxib in Treating Patients With Metastatic Colorectal Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00473980 2012-04-02
Preoperative Non-steroidal Anti-inflammatory Drugs(NSAID) to Colorectal Cancer Patients
Göteborg University
Phase 4 Completed
NCT00188565 2010-08-13
Celebrex With Preoperative Chemoradiation - Rectal Cancer
University Health Network, Toronto
Phase 1/2 Completed
NCT00001693 2008-03-04
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
National Institutes of Health Clinical Center (CC)
Phase 1 Completed